PL1605932T3 - Donosowa kompozycja farmaceutyczna z rotigotyną - Google Patents

Donosowa kompozycja farmaceutyczna z rotigotyną

Info

Publication number
PL1605932T3
PL1605932T3 PL04804221T PL04804221T PL1605932T3 PL 1605932 T3 PL1605932 T3 PL 1605932T3 PL 04804221 T PL04804221 T PL 04804221T PL 04804221 T PL04804221 T PL 04804221T PL 1605932 T3 PL1605932 T3 PL 1605932T3
Authority
PL
Poland
Prior art keywords
rotigotine
intranasal formulation
cyclodextrin
alpha
viscosity
Prior art date
Application number
PL04804221T
Other languages
English (en)
Inventor
Robert Krämer
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of PL1605932T3 publication Critical patent/PL1605932T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04804221T 2003-12-23 2004-12-22 Donosowa kompozycja farmaceutyczna z rotigotyną PL1605932T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03029680A EP1547592A1 (en) 2003-12-23 2003-12-23 Intranasal formulation of rotigotine
PCT/EP2004/014626 WO2005063236A1 (en) 2003-12-23 2004-12-22 Intranasal formulation of rotigotine
EP04804221A EP1605932B1 (en) 2003-12-23 2004-12-22 Intranasal formulation of rotigotine

Publications (1)

Publication Number Publication Date
PL1605932T3 true PL1605932T3 (pl) 2006-09-29

Family

ID=34530709

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04804221T PL1605932T3 (pl) 2003-12-23 2004-12-22 Donosowa kompozycja farmaceutyczna z rotigotyną

Country Status (27)

Country Link
US (1) US7683040B2 (pl)
EP (2) EP1547592A1 (pl)
JP (1) JP4430067B2 (pl)
KR (1) KR100718760B1 (pl)
CN (1) CN100374112C (pl)
AT (1) ATE326961T1 (pl)
AU (1) AU2004308641B2 (pl)
BR (1) BRPI0407845A (pl)
CA (1) CA2516400C (pl)
CY (1) CY1105131T1 (pl)
DE (1) DE602004000982T2 (pl)
DK (1) DK1605932T3 (pl)
EA (1) EA008005B1 (pl)
ES (1) ES2262122T3 (pl)
HR (1) HRP20060240T3 (pl)
IL (1) IL170297A (pl)
IS (1) IS2310B (pl)
MX (1) MXPA05008909A (pl)
NO (1) NO20054018L (pl)
NZ (1) NZ541875A (pl)
PL (1) PL1605932T3 (pl)
PT (1) PT1605932E (pl)
RS (1) RS50534B (pl)
SI (1) SI1605932T1 (pl)
UA (1) UA79196C2 (pl)
WO (1) WO2005063236A1 (pl)
ZA (1) ZA200506550B (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
EP1426049B1 (en) 2002-12-02 2005-05-18 Schwarz Pharma Ag Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
EA017836B1 (ru) 2007-11-28 2013-03-29 ЮСиБи ФАРМА ГМБХ Новая полиморфная форма ротиготина и способ ее получения
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
CN104189912A (zh) 2009-12-22 2014-12-10 优时比制药有限公司 用于使非结晶形式的罗替戈汀的固体分散体稳定化的聚乙烯吡咯烷酮
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
WO2013075823A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
CN103768043B (zh) * 2012-10-22 2015-12-09 苏州药明康德新药开发股份有限公司 采用羟丙基-β-环糊精配制四氢化萘类化合物均一稳定溶液的方法
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
US10046151B2 (en) 2013-07-03 2018-08-14 Lts Lohmann Therapie-Systeme, Ag Transdermal therapeutic system with electronic component
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物
WO2015177212A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
WO2015177209A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
US11633367B2 (en) 2014-05-20 2023-04-25 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
CN110917125B (zh) * 2020-01-02 2022-08-12 安徽中医药大学 一种罗替戈汀鼻用胶束温敏凝胶的制备方法
US12569493B2 (en) 2020-03-24 2026-03-10 Cyrano Therapeutics Inc. Treatment of chemosensory dysfunction from a coronavirus infection
JP2025502075A (ja) * 2022-01-06 2025-01-24 シラノ セラピューティクス， インコーポレイテッド パーキンソン病治療剤の改善された鼻投与
CN120053353A (zh) * 2024-05-31 2025-05-30 纳索菲德(上海)制药技术有限公司 一种巴氯芬鼻脑递释组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108991A (en) * 1975-06-19 1992-04-28 Whitby Research, Inc. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4992422A (en) * 1986-01-31 1991-02-12 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
DE3783683T2 (de) * 1986-01-31 1993-05-19 Whitby Research Inc Hautpenetration verbessernde zusammensetzungen.
US5218113A (en) * 1986-01-31 1993-06-08 Whitby Research, Inc. N-substituted thiolactams
US4755535A (en) * 1986-04-23 1988-07-05 Nelson Research & Development Co. Compositions comprising 1-substituted azacycloalkenes
US5073544A (en) 1986-08-15 1991-12-17 Whitby, Inc. Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes
US4902676A (en) * 1986-09-29 1990-02-20 Nelson Research & Development Co. Compositions comprising N,N-dialkylalkanamides
DE3868866D1 (de) * 1987-11-20 1992-04-09 Erba Carlo Spa Ergolinderivate mit antiparkinsonwirkung.
US5472946A (en) * 1988-04-08 1995-12-05 Peck; James V. Transdermal penetration enhancers
US5073844A (en) * 1991-01-11 1991-12-17 The Annlouise Partnership Lighted baggage piece
US6086905A (en) * 1991-03-21 2000-07-11 Peck; James V. Topical compositions useful as skin penetration barriers
US5308625A (en) * 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5756483A (en) * 1993-03-26 1998-05-26 Merkus; Franciscus W. H. M. Pharmaceutical compositions for intranasal administration of apomorphine
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
US5771890A (en) * 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
CA2193885C (en) 1994-06-24 2003-11-25 Janet Tamada Iontophoretic sampling device and method
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
EP1344522A1 (en) 2001-05-08 2003-09-17 Schwarz Pharma Ag Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
FR2829028B1 (fr) * 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
MXPA04009352A (es) * 2002-04-18 2005-01-25 Pharmacia Corp Terapia de combinacion para el tratamiento de la enfermedad de parkinson con inhibidores de ciclooxigenasa-2 (cox2).
WO2004039320A2 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
EP1708706A1 (en) * 2004-01-22 2006-10-11 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
AU2005270468A1 (en) 2004-08-02 2006-02-16 Schwarz Pharma Ag Indolizine carboxamides and the aza and diaza derivatives thereof
DE102004054634A1 (de) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide

Also Published As

Publication number Publication date
PT1605932E (pt) 2006-08-31
HK1083596A1 (en) 2006-07-07
KR100718760B1 (ko) 2007-05-15
IS2310B (is) 2007-11-15
MXPA05008909A (es) 2005-10-05
NZ541875A (en) 2008-08-29
CY1105131T1 (el) 2009-11-04
US20070191308A1 (en) 2007-08-16
CA2516400C (en) 2009-10-27
CA2516400A1 (en) 2005-07-14
BRPI0407845A (pt) 2006-02-14
KR20060040578A (ko) 2006-05-10
IL170297A (en) 2010-06-30
CN100374112C (zh) 2008-03-12
SI1605932T1 (sl) 2006-08-31
EA008005B1 (ru) 2007-02-27
EA200501159A1 (ru) 2006-02-24
WO2005063236A1 (en) 2005-07-14
UA79196C2 (en) 2007-05-25
RS50534B (sr) 2010-05-07
EP1605932A1 (en) 2005-12-21
ES2262122T3 (es) 2006-11-16
AU2004308641A1 (en) 2005-07-14
ZA200506550B (en) 2006-05-31
ATE326961T1 (de) 2006-06-15
EP1547592A1 (en) 2005-06-29
DK1605932T3 (da) 2006-09-18
DE602004000982T2 (de) 2007-05-10
DE602004000982D1 (de) 2006-06-29
IS8487A (is) 2006-05-26
HRP20060240T3 (hr) 2007-05-31
JP2006526004A (ja) 2006-11-16
CN1777422A (zh) 2006-05-24
NO20054018L (no) 2005-08-30
US7683040B2 (en) 2010-03-23
JP4430067B2 (ja) 2010-03-10
EP1605932B1 (en) 2006-05-24
AU2004308641B2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
SI1605932T1 (sl) Intranazalna formulacija rotigotina
NO20061840L (no) Legemiddelbelegg som tilveiebringer hoy legemiddeltilsetning og fremgangsmater for a tilveiebringe samme
BR0011433A (pt) Imidazoquinolinas substituìdas com sulfonamida e sulfamida
HRP20040352B1 (en) Use of flibanserin in the treatment of sexual disorders
ATE546135T1 (de) Hyaluronsäure-nanopartikel
EP1539122A4 (en) PHARMACEUTICAL AQUEOUS 2,6-DIISOPROPYLPHENOL COMPOSITIONS
GEP20074027B (en) Stabilized oral suspension formulation
AU2001260455A1 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
BR0209020A (pt) Composição farmacêutica de polialilamina
DE60221227D1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen
HRP20010878B1 (en) Ziprasidone suspension
WO2005056515A3 (en) Use of bis-amines to enhance the antimicrobial activity of aqueous compositions
BR0010150A (pt) Solução oral de prucalopride
AU2002358819A1 (en) Aqueous base liquid pharmaceutical compositions in suspension form for the oral administration of ibuprofen
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
WO2003009835A3 (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
WO2003030862A3 (en) Anaesthetic compositions and method for their administration
AU2001258754A1 (en) Aqueous liquid preparation
WO2010066437A3 (de) Wässrige zusammensetzung enthaltend dexpanthenol und natriumchlorid
BR0011845A (pt) Complexo farmacêutico
IS8428A (is) Innrennslislyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
PT1093810E (pt) Comprimido de dissolucao rapida contendo brotizolam
FR2864090B1 (fr) Derives carboxy-reduits de l'acide hyaluronique, leur preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant
WO2005035746A3 (en) Medical use of tbk-1 or of inhibitors thereof
MXPA04000918A (es) Pramipexol como anticonvulsivo.